

Supplementary Table S2. ADA impact to landmark PSA50 response at 12 weeks

	N[†]	Reached 12 weeks time-on-treatment[‡] (n)	PSA50 at 12 weeks[§] n (%)
ADA-positive*	54	39	23 (59%)
ADA-negative	36	12	7 (58%)

*ADA-positive includes patients that developed ADAs at any time during this study.

[†]N includes 90 evaluable patients with both a baseline and post-baseline result.

[‡]The 12-week timepoint is determined by either 87 days after the first dose of xaluritamig, or the Cycle 4 D1 assessment, whichever is later.

[§]PSA50 at 12 weeks defined as achieving the PSA response (PSA 50) at or prior to 12 weeks after the first dose of xaluritamig.

ADA, antidrug antibodies; D, day; PSA, prostate-specific antigen.